Firing Up the Tumor Microenvironment in Metastatic Prostate Cancer with Synergistic PSMA-Targeting Radioligands and STING Agonist Nanotherapies
Abstract
Outcomes for patients with metastatic prostate cancer remain poor. There is thus an unmet clinical need to develop new therapy approaches to manage this disease. Given poor results to date of immunotherapy treatment for prostate cancer, likely due to the immunosuppressive nature of the tumor microenvironment, new ways to augment the localized anti-tumor inflammatory response are needed. This proposal aims to explore the synergy of two highly promising types of treatment for prostate cancer for this purpose. The systemically targeted radionuclide therapy 177 Lu-PSMA-617 has shown high potential to reduce patient disseminated disease burden and is poised to be FDA-approved in the near future. Radiation therapy is known to modulate the tumor immune environment and may potentially augment the effects of other promising immunotherapies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2023
- Accession Number
- AD1195579
Entities
People
- Sheung Ng
Organizations
- Massachusetts General Hospital